Position in GLSI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$616,304
+$297,397 QoQ
Shares Held
25,658
-19.9% QoQ
Ownership
0.175%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in GLSI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MARSHALL WACE, LLP holds $2,756,303,735 across 280 Biotechnology names. GLSI ranks #214 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,099,318 | $363,731,344 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
317,058 | $141,579,078 | |
| 3 | INCY |
Incyte Corp
|
1,253,138 | $117,945,347 | |
| 4 | RPRX |
Royalty Pharma plc
|
2,120,692 | $101,729,594 | |
| 5 | RCUS |
Arcus Biosciences, Inc.
|
3,761,437 | $81,247,039 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
628,075 | $66,199,104 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
2,246,943 | $62,240,320 | |
| 8 | COGT |
Cogent Biosciences, Inc.
|
1,600,168 | $61,590,466 |
All Filings in GLSI
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $616,304 | 25,658 | Shares | Other | 2026-05-15 | |
| 2025-09-30 | $318,907 | 32,051 | Shares | Other | 2025-11-13 | |
| 2025-06-30 | $509,207 | 56,142 | Shares | Other | 2025-08-13 | |
| 2023-03-31 | $593,397 | 43,031 | Shares | Other | 2023-05-15 | |
| 2022-12-31 | $646,045 | 42,503 | Shares | Other | 2023-02-14 | |
| 2022-09-30 | $699,998 | 76,923 | Shares | Other | 2022-11-14 | |
| 2022-06-30 | $760,063 | 89,736 | Shares | Other | 2022-08-15 | |
| 2022-03-31 | $410,156 | 20,905 | Shares | Other | 2022-05-16 | |
| 2021-12-31 | $431,103 | 17,719 | Shares | Other | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||